Background: The impact of dermatology consultation on the care of children with oncologic conditions is unknown.
1
Correspondingly, reactions and complications from cancer therapy have increased, as has the need for long-term surveillance for secondary neoplasms, especially in pediatric patients. [1] [2] [3] [4] From Harvard Medical School a There are limited data on the impact of dermatology involvement on the care of these children. Prior studies of the epidemiology of skin conditions and the role of dermatologists in the care of pediatric patients were not specific to the pediatric oncology population. [5] [6] [7] The objectives of this study were to determine the characteristics of outpatient dermatology visits and the resulting impact on diagnosis and management of pediatric oncology patients.
METHODS Overview
The medical records of all patients with a Dana-Farber Cancer Institute medical record number and a dermatology clinic visit at Boston Children's Hospital from 2008 to 2015 were retrospectively reviewed for demographic and medical information. Inclusion criteria included an oncologic diagnosis and/or diagnosis requiring a hematopoietic stem cell transplant (HSCT) and a dermatology visit from 2008 to 2015. Exclusion criteria included the absence of a dermatology visit after an oncologic diagnosis was made. Institutional review board approval was obtained through the Boston Children's Hospital (P00016307).
Data collection
Each medical record was reviewed for demographic and clinical information, including age, sex, race, distance from home to hospital, and cancer type and therapy. Dermatologic assessment and management, including treatment and procedures, were recorded from up to 4 visits for unique dermatology complaints in each patient. When there were multiple cutaneous findings (eg, atopic dermatitis or molluscum contagiosum), all diagnoses were included.
If available, preliminary assessment and management of the skin condition by the referring oncologist were recorded. Time from referral by the oncology service to the dermatology clinic appointment was recorded.
Study definitions
Change in diagnosis was defined as discordance between dermatology and oncology assessment of the skin condition. Oncology referrals for routine skin surveillance, in which the dermatologist documented benign melanocytic nevi, were categorized separately as skin surveillance.
Change in dermatologic management was defined as the addition, withdrawal, or change in dose of topical or systemic medication for a dermatologic condition. Change in medical management was defined as the addition, withdrawal, or change in dose of a systemic medication or procedure for a nondermatologic condition. When the oncologist documented a need for dermatology consultation regarding medications or procedures for nondermatologic issues, we categorized the subsequent dermatology visit as leading to a change in medical management. Changes in dermatologic and medical management were examined for all referrals from the oncology service. Diagnoses of significant impact were defined as adverse cutaneous drug reaction, cutaneous malignancy, herpes simplex virus (HSV) or varicella-zoster virus (VZV) infection, and graft-versus-host disease (GVHD) because of their potential for altering oncologic therapy.
Data analysis
Descriptive statistical analysis was performed with categorical data provided as frequencies and percentages and continuous data provided as means with standard deviations, and median values with ranges. Comparative statistical analysis was performed by using an unpaired t test and 2-tailed Fisher's test, utilizing GraphPad software (GraphPad Software, La Jolla, CA).
RESULTS
There were 1001 unique pediatric oncology patients seen by dermatologists from 2008 to 2015. The method of cohort selection is demonstrated in Fig 1. The medical records of 516 patients who met the inclusion and exclusion criteria were reviewed for demographic and clinical information. The medical records of 251 oncology patients with a documented oncology referral and a subsequent dermatology clinic visit were reviewed for the impact of dermatology consultation on diagnosis and treatment.
Demographic features
The The mean time from cancer diagnosis to dermatology visit was 65.2 months for routine skin screening. There was a significantly increased mean time from oncology referral to initial dermatology visit of 68.6 days (standard deviation, 90.2) for routine skin screening compared with 19.8 days (standard deviation, 34.1) for a specific cutaneous complaint (P \.001).
The most common reasons for initial consultation were skin issue after cancer therapy in 59.1% of patients (305 of 516) and skin cancer surveillance in 38.8% (200 of 516). Only 6.2% of patients (32) were referred before initiation of cancer therapy. A significantly higher proportion of HSCT recipients were referred for routine skin cancer surveillance compared with patients who received other treatment regimens (26.1% vs 12.0% [P \.0001]).
Dermatologic characteristics are summarized in Table III . Dermatology consultation resulted in 827 diagnoses made during 743 visits, including skin infections in 21.3% of patients (176), adverse cutaneous drug reaction in 5.4% (45), cutaneous GVHD in 4% (33), and malignant lesion in 4.1% (34).
The most common infections were viral and bacterial, which accounted for 66.5% (117 of 176) and 14.2% (25 of 176) of infections, respectively. Of 45 patients experiencing adverse cutaneous drug reactions, 26.7% (12 patients) required temporary or permanent cessation of therapy, including for drug hypersensitivity reaction (not otherwise specified) (3 patients), morbilliform drug rash (2 patients), voriconazole-induced pseudoporphyria or photosensitivity (2 patients), linear immunoglobulin A dermatosis secondary to vancomycin (1 patient), drug reaction with eosinophilia and systemic symptoms (1 patient), acneiform eruption induced by cetuximab (1 patient), psoriasiform eruption due to sorafenib (1 patient), and methotrexate-induced ultraviolet radiation recall dermatitis (1 patient). Chronic cutaneous GVHD was diagnosed in 90.9% of patients with GVHD (30 of 33).
Malignant dermatologic diagnoses included squamous cell carcinoma (16 cases), basal cell carcinoma (5 cases), leukemia cutis or cutaneous lymphoma (4 cases), dermatofibrosarcoma protuberans (3 cases), melanoma (2 cases), cutaneous neuroblastoma (1 case), giant cell fibroblastoma (1 case), infantile fibrosarcoma (1 case), and Langerhans cell histiocytosis (1 case).
Other diagnoses were (1) skin eruptions (eg, atopic dermatitis, psoriasis, and seborrheic dermatitis) in 33.4% of visits (276 of 827 cases), (2) skin lesions (eg, congenital nevi, acrochordon, and seborrheic keratosis) in 20.3% (168 of 827 cases), and (3) miscellaneous diagnoses (predominantly changes in hair and nails) in 11.5% (95 of 827 cases).
A total of 118 skin biopsies were performed. Histopathologic examination yielded a definitive diagnosis in 87.3% of specimens (103 of 118): 9.3% of the biopsy specimens (11 of 118) were consistent with atypical nevi and 28.8% (34 of 118) were consistent with malignancy.
Impact on care of pediatric oncology patients
There were 251 pediatric patients with an initial oncology referral to dermatology from 2008 to 2015. Details regarding changes in diagnosis and management are listed in Table IV . At the initial visit, dermatology consultation resulted in a change in HSCT, Hematopoietic stem cell transplant. In 20.3% of cases (51 of 251), the referring oncologist was concerned about a diagnosis of significant impact, including an atypical or malignant lesion in 7.6% (19 of 251), adverse cutaneous drug reaction in 6.4% (16 of 251), GVHD in 5.6% (14 of 251), and HSV or VZV in 0.8% (2 of 251). The evaluating dermatologist provided an alternative, reassuring diagnosis in 43.1% of these cases (22 of 51).
Overall, there was a change in management of the dermatologic disease in 72.4% of patients. Change in management was made during 70% of visits (105 of 150) at which there was a change in diagnosis and in 77.6% (52 of 67) at which there was no change in diagnosis. The most frequent change in management was the addition of a topical agent (Table IV) .
Dermatology consultation resulted in changes in medical management in 12.4% of visits (31 of 251), including reassurance to continue systemic therapy in 51.6% (16 of 31), delay and/or cessation of systemic therapy in 16.1% (5 of 31), prevention of unnecessary systemic therapy in 9.7% (3 of 31), initiation of systemic therapy in 9.7% (3 of 31), and reassurance to continue procedures in 12.9% (4 of 31).
During the study period, there was a 72.6% increase in the number of unique pediatric oncology patients seen in the dermatology clinic and an 82.5% increase in the total number of dermatology visits (Fig 2) .
DISCUSSION
Dermatology evaluation affects the care of pediatric oncology patients by changing the diagnosis and management of cutaneous disease. Previous studies have demonstrated that dermatologists outperform generalists in making common skin diagnoses. [8] [9] [10] [11] Our results suggest that pediatric dermatologists similarly improve diagnostic accuracy, allowing for timely and appropriate intervention in the pediatric oncology population. Pediatric oncology patients have a high burden of disease long after completion of treatment. 12 Rare diagnoses may occur, and common cutaneous conditions may have severe and/or atypical presentations. Diagnostic accuracy has the potential to improve the quality of care.
Dermatology consultation may affect medical management of noncutaneous issues that have important implications for cancer therapy. Examples of changes in medical management in our study included reassurance to continue systemic therapy (eg, symptomatic management of a adverse cutaneous drug reaction that allowed for continuation of chemotherapy), delay of systemic therapy (eg, diagnosis of severe Coxsackie A6 infection that resulted in temporary cessation in chemotherapy), or reassurance to continue a procedure (eg, a diagnosis of arthropod assault when a surgical procedure was almost cancelled on account of a new rash of unknown etiology). Dermatologic involvement is important in the diagnosis of malignant disease in pediatric oncology patients. Cutaneous manifestation of visceral or hematologic malignancies in children may present as extramedullary hematopoiesis, leukemia cutis, or Langerhans cell histiocytosis. [13] [14] [15] [16] Pediatric cancer survivors are at increased risk for melanoma and nonmelanoma skin cancer, even during childhood. 17, 18 In our cohort, a primary cutaneous or noncutaneous malignancy accounted for 4.1% of diagnoses and 28.8% of skin biopsies; a high degree of suspicion for rare or malignant diagnoses is necessary in this population.
Our study found that dermatologists made a variety of other diagnoses requiring prompt intervention (ie, adverse cutaneous drug reaction, GVHD, HSV, or VZV) in 12.7% of initial visits in cases in which the oncologist had not considered these diagnoses. Dermatologists also play an important role by managing nonmalignant yet symptomatic disease and by providing reassurance to both patients and providers. The high frequency of common dermatologic diagnoses such as molluscum contagiosum and verruca vulgaris suggests that dermatologists should be prepared to manage ''benign'' viral infections in this population.
Oncologists at our institution recognize the need for skin surveillance in high-risk populations, as demonstrated by the frequent referral of HSCT recipients for skin cancer surveillance. HSCT recipients, particularly those with chronic GVHD, are at increased risk for skin cancer.
19-21 Guidelines on long-term follow-up currently recommend annual skin examinations for HSCT recipients. 22 There is a concerted, collaborative effort to address dermatologic complaints in pediatric oncology patients in a timely manner at our institution. Although previous studies have highlighted dermatology wait times ranging from 9.0 to 12.7 weeks, 23, 24 we found shorter wait times for patients presenting for both a specific cutaneous complaint and routine skin screening. The 72% increase in unique pediatric oncology patients seen at the dermatology clinic from 2008 to 2015 suggests a recognition of the value of dermatology input.
Our findings must be interpreted in the context of the study design. This was a single-center retrospective study at a pediatric tertiary academic center, and the study population may not be generalizable. The variation in documentation in medical records inherent to the retrospective design limited our ability to capture all referrals from the oncology service.
CONCLUSION
Dermatology consultation in the outpatient setting affects the care of pediatric oncology patients. Dermatologists can diagnose common nonmalignant cutaneous conditions that may have severe or atypical manifestations; recognize more concerning rare conditions, including cutaneous malignancies; and provide useful and collaborative input for critical medical decisions. There should be a low threshold to consult dermatology in the care of this unique population. 
